近日，浙江海正药业股份有限公司（以下简称"公司"）控股子公司浙江海正动物保健品有限公司（以下 简称"海正动保公司"）收到中华人民共和国农业农村部核准签发的甲泼尼龙片（犬用）《新兽药注册证 书》，该新兽药产品正式获批五类新兽药。现就相关情况公告如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、新兽药的基本情况 新兽药名称：甲泼尼龙片（犬用） 注册分类：五类 新兽药注册证书号：（2025）新兽药证字129号 截至目前，公司通过公开渠道未能获得市场其他公司上述同类产品具体销售收入数据。 二○二五年十二月十九日 三、风险提示 本次海正动保公司甲泼尼龙片（犬用）产品获得五类《新兽药注册证书》，标志着上述产品已符合《兽 药管理条例》和《兽药注册办法》相关规定，有利于进一步推动公司在兽药板块的战略布局，提升公司 市场竞争力。目前上述产品具备生产和上市条件，待取得兽药产品批准文号后上市，短期内不会对公司 业绩产生重要影响。敬请广大投资者注意投资风险。 特此公告。 董事会 研制单位：浙江海正动物保健品有限公司等7家公司 二、新兽药其他 ...

Core Viewpoint - Haizheng Pharmaceutical (600267) announced that its subsidiary, Zhejiang Haizheng Animal Health Products Co., Ltd., has received approval from the Ministry of Agriculture and Rural Affairs of the People's Republic of China for the new veterinary drug registration certificate for Nirocoxib Chewable Tablets, officially classified as a Class II new veterinary drug [1] Group 1 - The new veterinary drug, Nirocoxib Chewable Tablets, is intended for alleviating pain and inflammation caused by canine osteoarthritis and clinical surgeries [1] - The registration application for Nirocoxib Chewable Tablets was submitted in June 2022, and it was processed by the Ministry of Agriculture and Rural Affairs along with other entities [1] - The product is now ready for production and will be launched once it obtains the veterinary product approval number, but it is not expected to have a significant impact on the company's performance in the short term [1]